Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Metsera raised $275 million in its IPO ... Also on Thursday, Maze Therapeutics priced an upsized IPO at $16 a share, in the middle of a marketed range, according to a statement.

Sionna is working out its IPO plans days after obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics both listed on the Nasdaq with offerings of $275 million and $140 million ...

The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Its prospectus says that the IPO will fund phase 1 and phase ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze Therapeutics, which filed to list on ...

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated ...

Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...

Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...

Metsera expects its cash will last into 2027. Two other life science companies went public this past week. Here’s a look at those IPOs: Maze Therapeutics Finds Way to $140M IPO for Chronic ...